Skip to contentSkip to filters

We use cookies for analytics.

Seminar, Hosted by Xtalks

Overcome Barriers to Psychedelic Therapies for CNS Diseases

Bob Dagher, MD, Michael Gold, MD, Joseph Tucker, PhD and Alan Metz, MD

Clinilabs; Compass Pathways; Enveric Biosciences; Alan Metz Consulting LLC

Abstract

Clinical development of psychedelic therapies raises questions about blinding, treatment setting, safety monitoring and the durability of response. The panel examines how those features affect trials in psychiatric conditions and the evidence required to evaluate therapeutic benefit.

Topics